In contrast, the combination of cisplatin with the DNA or protein-based vaccines promoted a significant increase in circulating E7-specific CD8+ T cells (Fig. 1B ), led to enhanced tumor control (Fig. 1C; Fig. S1) and complete tumor regression in 70% or 80% of the immunized mice, respectively (Fig. 1D). Here, CD8A is linked to neoplasm.